https://www.selleckchem.com/products/bi-3231.html
6% acromegaly, 37.1% prolactinomas, and 14.3% non-functioning pituitary adenomas). The median number of temozolomide (TMZ) cycles was 9 (IQR 6-14). Responders constituted 68.6% of the cohort and were more likely to have functional tumors, a lower percentage of MGMT-positive staining cells, and lower MGMT -scores. There was a significantly longer lag period in the initiation of TMZ therapy in non-responders as compared with responders (median 36 . 15months, =0.01). ROC-derived cutoffs of 31months for the duration between diagnosis and TM
Like
Comment
Share
